Johnson & Johnson
Open
$235.13
Prev. Close
$235.10
High
$235.67
Low
$235.13
Market Snapshot
$566.76B
26.9
5.84
$88.82B
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Johnson & Johnson announces a $55 billion investment in U.S. manufacturing, aiming to create thousands of jobs and enhance local production and innovation capabilities.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Recently from Cashu
Johnson & Johnson Launches TECNIS PureSee Lens, Enhancing Vision Correction for Cataract Patients
Johnson & Johnson (Ticker: JNJ) announces the U.S. launch of its TECNIS PureSee intraocular lens, a groundbreaking development in vision correction for cataract patients. Designed specifically for tho…
Johnson & Johnson's IMAAVY Shows Promising Results in Treating Warm Autoimmune Hemolytic Anemia
Johnson & Johnson (Ticker: JNJ) advances its position in the healthcare sector with promising results from its drug IMAAVY, an innovative treatment for warm autoimmune hemolytic anemia (wAIHA). The Ph…
Johnson & Johnson Advances Drug Development for Autoimmune and Oncological Conditions with Nipocalimab
Johnson & Johnson (Ticker: JNJ) makes strides in the healthcare industry with promising advances in its drug development pipeline, particularly with nipocalimab. Recent data from clinical trials showc…
TREMFYA® Approved: Johnson & Johnson’s Breakthrough in Psoriatic Arthritis Treatment
Johnson & Johnson (Ticker: JNJ) announces a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of a supplemental Biologics License Application for its medication TREMFYA…